ClinicalTrials.gg
RecruitingNCT07306949ATTR-CMUpdated Jan 7, 2026

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

A Phase 4 interventional study of Acoramidis in Transthyretin-type Cardiac Amyloidosis, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 16 sites in Japan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Amyloidosis with a site in Japan — 10 open to participants now, 12 under way, 7 of them phase 3. Amyloidosis · Japan.

Planned enrollment
15th of 21
200 · median 360
Started
2025
with 2 others
Phase 4
Only one
of the 24
Primary completion
2028-03
later than 7 of 11 live
Registered
24th of 24
by date
Lead sponsor
2 of 24
Alexion Pharmaceuticals, Inc.

Among the 24 studies in Amyloidosis with a site in Japan, this one is the 15th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 4, reaches primary completion later than 7 of the 11 other live ones, and was the 24th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

10 of the 24 studies in Amyloidosis with a site in Japan are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Amyloidosis with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.

03

Conditions studied

  • Transthyretin-type Cardiac Amyloidosis

Browse trials for

Keywords

  • ATTR-CM
  • NT-proBNP
  • ODI
  • hs-cTnT
  • Acoramidis
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment history of ATTR-CM is one of the following:
  • Naive participants: newly diagnosed with ATTR-CM and no prior treatment with drugs for ATTR-CM
  • Switch participants: Participants who are using tafamidis, a TTR stabilizer, as treatment for ATTR-CM and who, in the judgment of the post-marketing clinical trial investigator (co-principal investigator), can be expected to benefit from switching to acoramidis.
  • Naive participants must meet the following requirements:

    1. History of hospitalization for heart failure or heart failure symptoms requiring treatment, including diuretics
    2. Echocardiographic end-diastolic ventricular septal thickness greater than 12 millimeters (mm)
    3. Confirmed diagnosis of ATTR-CM (wild type or mutant) by one of the following diagnostic methods

      1. Tissue shows amyloid deposition and TTR precursor protein is identified by immunohistochemistry or mass spectrometry.
      2. Bone scintigraphy showing strong accumulation ** (Perugini score ≥ 2) consistent with myocardium and no M protein, negating the possibility of AL amyloidosis

Exclusion criteria

Exclusion Criteria:

  • Have confirmed diagnosis of AL amyloidosis
  • Switch participants: prior treatment with gene silencing agents (pachysilane sodium, butrisilane sodium) as treatment for ATTR-CM (including when specifically scheduled to start treatment with a gene silencing agent)
  • Likelihood of receiving a heart transplant within 1 year from the time screening begins
  • to acoramidis, its metabolites, or additives in the formulation has been confirmed.
  • Pregnant or lactating women
  • Has a medical condition, an abnormal laboratory test result, or a condition that may jeopardize the safety of the study participant, increase the risk of participation in the post-marketing clinical trial, or affect the study
  • Participating in an interventional study other than this study, including a clinical trial
  • In the opinion of the responsible (sub)physician for the post-marketing clinical trial, has a history of drug abuse, alcoholism, or psychiatric disorder that would preclude compliance with this Post-Marketing Clinical Study Protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Acoramidis

    Participants will receive 800 mg of acoramidis twice daily for 18 months.

    Drug: Acoramidis

Interventions

  • Participants will receive acoramidis tablets orally.

    Also known as: acoramidis hydrochloride Byontra

06

What researchers measure

Primary outcomes

  1. Disease Progression Rate as Measured by N-terminal pro-brain-type Natriuretic Peptide (NT-proBNP) and/or Outpatient Diuretic Intensification (ODI)

    Time frame: Baseline through 12 months

Secondary outcomes

  1. Disease Progression Rate as Measured by NT-proBNP and/or High-sensitivity Cardiac Troponin T (hs-CTnT)

    Time frame: Baseline through 12 months

  2. Change from Baseline in Serum Transthyretin (TTR)

    Time frame: Baseline, 28 days

  3. Number of Participants with a 30% Change from Baseline in NT-proBNP

    Time frame: Baseline, 12 months and 18 months

  4. Change from Baseline in hs-CTnT

    Time frame: Baseline, 12 months and 18 months

  5. Change from Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) Overall Summary Score

    Time frame: Baseline, 12 months and 18 months

  6. Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline, 12 months and 18 months

07

Study locations

2 of 16 sites recruiting
  • Research Site
    Bunkyō City, 113-8431, Japan
    Not yet recruiting
  • Research Site
    Bunkyō City, 113-8603, Japan
    Not yet recruiting
  • Research Site
    Kumamoto, 860-8556, Japan
    Not yet recruiting
  • Research Site
    Kurume-shi, 830-0011, Japan
    Recruiting
  • Research Site
    Kyoto, 606-8507, Japan
    Not yet recruiting
  • Research Site
    Mitaka-shi, 181-8611, Japan
    Not yet recruiting
  • Research Site
    Nagoya, 466-8560, Japan
    Not yet recruiting
  • Research Site
    Nankoku-shi, 783-8505, Japan
    Not yet recruiting
  • Research Site
    Okayama, 700-8558, Japan
    Not yet recruiting
  • Research Site
    Ōtsu, 520-2192, Japan
    Not yet recruiting
  • Research Site
    Sagamihara-shi, 252-0375, Japan
    Not yet recruiting
  • Research Site
    Sapporo, 060-8543, Japan
    Not yet recruiting
  • Research Site
    Shinjuku-ku, 160-8582, Japan
    Not yet recruiting
  • Research Site
    Suita-shi, 564-8565, Japan
    Not yet recruiting
  • Research Site
    Tsu, 514-8507, Japan
    Not yet recruiting
  • Research Site
    Yufu-shi, 879-5593, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07306949
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Oct 1, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jan 7, 2026

Study contacts

Alexion Pharmaceuticals, Inc. (Sponsor)
Contact
clinicaltrials@alexion.com
1-855-752-2356

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acoramidis

Start the discussion